Why AMD Stock Just Lit Up 4%
Don’t worry, AMD investors. The semiconductor crunch isn’t disappearing anytime soon.
Mindfully Curated
Don’t worry, AMD investors. The semiconductor crunch isn’t disappearing anytime soon.
Sales are coming in hot but the company isn’t as profitable as it originally expected.
Investors were not pleased by its first earnings report as a public company.
Management lowers guidance as the delta variant slows growth.
A down week was capped off with news that founder Sir Richard Branson sold a large amount of stock.
One Wall Street analyst has seen enough.
The biopharma company’s second quarter was better than expected. The future looks pretty bright, too.
The chipmaker has had a rough week as the global semiconductor shortage weighs on investor sentiment and analysts warn of challenges ahead.
Earnings beat estimates, but the automaker’s outlook isn’t so rosy.
The materials processing company reported second-quarter results and provided updates for investors.
SXI earnings call for the period ending June 30, 2021.
Biogen is reeling from charges that its drug doesn’t work.
A team of researchers found that people considered websites more interactive if they had tools to facilitate communication between users, often referred to as computer-mediated communication, or CMC.
Pre-mRNA splicing in a subset of human short introns is governed by a distinct mechanism involving a new splicing factor, new research finds.
The initials BRCA2 may be best known for a gene associated with many cases of breast cancer, and the protein encoded by the BRCA2 gene is critical to repairing breaks in DNA. The breakdown of this interaction is a hallmark of many cancers. Now scientis…
A wider loss than expected is part of the story, but there’s more.
Researchers are analyzing new materials for electrical insulation, or packaging, that can remove heat more effectively compared to today’s insulation, amid a need to redesign our electrical infrastructure for the next 100 years and beyond to match adva…
A team of researchers have developed a new way to tag tumor cells to figure out how they evolve and change over time to resist cancer treatments.
Researchers have identified new biomarkers that may advance the early detection of diabetic retinopathy, the most common diabetic eye disease and a leading cause of blindness in U.S. adults.
All three have the potential to generate multibagger returns.